Tyra Biosciences Stock Today
| TYRA Stock | USD 16.00 0.28 1.78% |
Performance0 of 100
| Odds Of DistressLess than 20
|
Tyra Biosciences is trading at 16.00 as of the 29th of November 2024, a 1.78 percent increase since the beginning of the trading day. The stock's open price was 15.72. Tyra Biosciences has about a 20 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Tyra Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of September 2024 and ending today, the 29th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of September 2021 | Category Healthcare | Classification Health Care |
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California. The company has 50.6 M outstanding shares of which 1.87 M shares are at this time shorted by private and institutional investors with about 3.29 trading days to cover. More on Tyra Biosciences
Moving against Tyra Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Tyra Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President, CoFounder | Todd Harris | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsTyra Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Tyra Biosciences' financial leverage. It provides some insight into what part of Tyra Biosciences' total assets is financed by creditors.
| |||||
Tyra Biosciences (TYRA) is traded on NASDAQ Exchange in USA. It is located in 2656 State Street, Carlsbad, CA, United States, 92008 and employs 49 people. Tyra Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 809.65 M. Tyra Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 50.6 M outstanding shares of which 1.87 M shares are at this time shorted by private and institutional investors with about 3.29 trading days to cover.
Tyra Biosciences currently holds about 275.11 M in cash with (50.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.61.
Check Tyra Biosciences Probability Of Bankruptcy
Ownership AllocationTyra Biosciences shows a total of 50.6 Million outstanding shares. The majority of Tyra Biosciences outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Tyra Biosciences to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Tyra Biosciences. Please pay attention to any change in the institutional holdings of Tyra Biosciences as this could imply that something significant has changed or is about to change at the company. Also note that roughly one million eight hundred sixty-seven thousand two hundred fifty-one invesors are currently shorting Tyra Biosciences expressing very little confidence in its future performance.
Check Tyra Ownership Details
Tyra Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 523.2 K | |
| Perceptive Advisors Llc | 2024-09-30 | 511.2 K | |
| Kynam Capital Management, Lp | 2024-09-30 | 467.9 K | |
| Sio Capital Management, Llc | 2024-09-30 | 400.9 K | |
| State Street Corp | 2024-06-30 | 368.5 K | |
| Jpmorgan Chase & Co | 2024-06-30 | 364.8 K | |
| Ally Bridge Group (ny) Llc | 2024-09-30 | 270.1 K | |
| Northern Trust Corp | 2024-09-30 | 214.4 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 173.7 K | |
| Ra Capital Management, Llc | 2024-09-30 | 10.4 M | |
| Boxer Capital Llc | 2024-09-30 | 6.4 M |
Tyra Biosciences Historical Income Statement
Tyra Stock Against Markets
Tyra Biosciences Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Sarah Honig | Vice Strategy | Profile | |
| Amy Conrad | Investor Contact | Profile | |
| Douglas MD | Chief Officer | Profile | |
| Hiroomi MD | Chief Officer | Profile | |
| Lynn Scherm | F Director | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tyra Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Tyra Stock refer to our How to Trade Tyra Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tyra Biosciences. If investors know Tyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tyra Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.61) | Return On Assets (0.20) | Return On Equity (0.29) |
The market value of Tyra Biosciences is measured differently than its book value, which is the value of Tyra that is recorded on the company's balance sheet. Investors also form their own opinion of Tyra Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Tyra Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tyra Biosciences' market value can be influenced by many factors that don't directly affect Tyra Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tyra Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tyra Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tyra Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.